Full-Time

Sr. Mgr. Customs Services & Projects

Confirmed live in the last 24 hours

Pfizer

Pfizer

10,001+ employees

Develops and manufactures vaccines and medicines

Social Impact
Biotechnology
Healthcare

Senior, Expert

Pointe-Claire, QC, Canada + 2 more

More locations: Mississauga, ON, Canada | Brandon, MB, Canada

The job may require presence in one of the specified Pfizer sites in Belgium or Canada.

Category
Procurement & Sourcing
Quality Control & Compliance
Supply Chain Management
Operations & Logistics

You match the following Pfizer's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s Degree in international trade, supply chain logistics or related field and 7 – 10 years of experience of import and / or export, vendor management and other trade compliance operations preferably in a pharmaceutical industry, consultancy services.
  • 5+ years of project management experience, including tracking, planning and implementation projects.
  • Expert knowledge of import and export regulations, customs laws, trade sanctions, embargoes, licensing requirements and trade agreements such as free trade agreements and preferential trade arrangements.
  • Interpersonal skills to influence and spit change, facilitate and enhance performance within a cross functional environment.
  • In-depth knowledge and experience with internal and external regulatory audit programs.
  • Experience with leading, executing and maintaining Compliance programs.
  • Ability to prioritize, quickly synthesize information and apply regulatory requirements to a variety of scenarios.
  • Must exercise excellent judgment, make decisions based on a clear understanding of the regulations, deploying strategies to conduct compliant business.
  • Strong negotiation, communication, and relationship – building skills as well, problem – solving, decision - making and presentation capabilities.
  • Creative, curious and adaptive learner willing to seek out continuous improvement opportunities while minimizing business risk and driving the Company to meet objectives across multiple areas.
Responsibilities
  • Ensure the direction and strategy that allows operational flexibility, efficiencies, and risk mitigation in collaboration with customs service vendors (brokers).
  • Ensure the design and maintenance of a structured, fit-for-purpose framework of vendor governance to ensure effective oversight and management of all customs outsourced activities.
  • Responsible for the regularly reviews total scope of outsourced services from an operational perspective to ensure effective management of resources and identify opportunities for continuous improvement.
  • Research and brings forward industry trends, partnership management, innovation in the field of customs service vendor and best practices beneficial to GLNS organization.
  • Responsible to set goals and objectives for the customs service’s vendor function aligned with GLNS focus areas.
  • Manage and establish appropriate metrics, KPIs and scorecards to measure performance, health of the partnership and achievement of goals and objectives.
  • Collaborates with Global Transportation Solution, Procurement and Global Trade Compliance to establish efficient and effective contracting processes to ensure all vendor contracts are in place achieving GLNS critical milestones.
  • Partners with Global Procurement, Global Transportation Solution and Global Trade Compliance functions the selection and onboarding of new vendors.
  • Operationally ensure service and partnership-level issues resolution.
  • Run the customs projects on a day – to – day basis, making sure that the project produces the required deliverable within the specified constraints of time and cost, and achieve desired results.
  • Serve as a customs and compliance operational expert matter, providing strategic insights and recommendations.
  • Orchestrate at a global level in partnership of key stakeholders’ litigation management process.
  • Advice on the compliance implication of operational decisions. Stay ahead of trends and challenges, proactively advising on potential impacts and opportunities.
  • Identify and assess potential compliance risk related to customs and compliance operational activities, developing strategies to mitigate risk.
  • Lead and mentor customs and compliances operational teams, fostering a strong culture of compliance.
  • Develop and deliver training programs for colleagues on customs and compliance operations, ensuring awareness and understanding across the organization.
  • Establish metrics and reporting mechanism to measure effectiveness of the customs and compliance operations program.
Desired Qualifications
  • Master’s degree.
  • At least 3-5 years in leadership roles. Ability to lead customs operations and compliance team with a leadership approach that energizes, motivates and facilitate teamwork while encouraging innovative ideas, approaches and accountability.
  • SAP GTS Knowledge.
  • Professional trade certifications or similar.
  • PMP certified.
  • Proven track record driving positive change in a complex environment.
  • Demonstrate strong problem – solving skills based on facts, data and understanding of the regulatory requirement in complex and evolving environments; must be able to apply sound risk management.
  • Able to handle organizational complexity and ambiguity.

Pfizer is a biopharmaceutical company that focuses on creating and manufacturing healthcare products, including medicines and vaccines. The company conducts extensive research and development to discover new treatments, which are then commercialized and sold to various clients such as governments, healthcare providers, and patients. Pfizer's products include vaccines, oncology treatments, and specialized medicines. A notable achievement is its partnership with BioNTech to develop a vaccine for COVID-19, which has played a significant role in addressing the pandemic. Pfizer aims to improve public health by providing access to vaccines, especially in underserved areas, and continues to grow its product offerings with new approvals and treatments.

Company Size

10,001+

Company Stage

IPO

Total Funding

$3.8B

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Starboard Value's $1 billion stake may drive strategic changes and increase shareholder value.
  • Pfizer's investment in fibrosis treatments expands its therapeutic areas.
  • Involvement in protein modification research diversifies Pfizer's treatment offerings.

What critics are saying

  • Slowdown in COVID-19 vaccine demand impacts Pfizer's revenue streams.
  • Activist investor Starboard Value may influence Pfizer's strategic decisions.
  • Emerging biotech companies pose a threat to Pfizer's market share in immunotherapy.

What makes Pfizer unique

  • Pfizer's partnership with BioNTech led to a highly effective COVID-19 vaccine.
  • Pfizer invests in AI disease models, enhancing predictive insights for drug development.
  • Pfizer's oncology portfolio is strengthened by investments in TCR-based immunotherapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Business Wire
Jan 16th, 2025
Normunity Closes $75 Million Series B Financing to Advance Lead Drug Program Into the Clinic and Broaden Pipeline of Novel Anti-Cancer Therapies Targeting Untapped Drug Mechanisms

Normunity, a biotechnology company creating novel anti-cancer therapies, today announced that it has closed a Series B financing for $75 million. The

TechCrunch
Oct 23rd, 2024
Promise Bio exits stealth backed by Pfizer and AstraZeneca | TechCrunch

The company has made it easier to test for different protein modifications which are critical to the treatment of autoimmune diseases.

The Wall Street Journal
Oct 7th, 2024
Exclusive | Activist Starboard Value Takes $1 Billion Stake in Pfizer

The drugmaker’s shares have slumped as demand for Covid-19 vaccines and treatments had slowed.

Benzinga
Oct 3rd, 2024
Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®

New investors Pfizer Ventures and M Ventures co-led the financing, with participation from all existing investors including RA Capital, Samsara BioCapital and SV Health InvestorsEnara Bio's EDAPT® platform is

Business Wire
Jul 18th, 2024
CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts

CytoReason, a leader in developing computational disease models for predictive insights, announced today it secured an aggregated $80 million from Our

Business News This Week
Feb 23rd, 2024
Colorcon Ventures Invests in Vedanta Biosciences, a Clinical-Stage Microbial Therapeutics Company

Colorcon Ventures joins a prominent list of investors who also participated in Vedanta’s fundraising round, including AXA IM Alts, The AMR Ac

GlobeNewswire
Jan 30th, 2024
COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha Wave Ventures

Funds will be used to support the advancement of COUR’s Myasthenia Gravis (MG) and Type 1 Diabetes (T1D) product candidates into Phase 2a clinical...

MarketBeat
Jan 10th, 2024
TIAA Trust National Association Invests $17.55 Million in Pfizer Inc. (NYSE:PFE)

TIAA Trust National Association invests $17.55 million in Pfizer Inc. (NYSE:PFE).

Business Wire
Oct 11th, 2023
Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline

Agomab Therapeutics NV (‘Agomab’) today announced the closing of a $100 million (€94.9 million) Series C financing round led by Fidelity Management &a

Web Capital Riesgo
Oct 11th, 2023
Agomab, participada de Asabys, cierra una Series C de $100M con Fidelity, EQT Life Sciences, Canaan, KKR, Asabys y Pfizer - Webcapitalriesgo

11/10/2023 Nota de prensa GOMAB, PARTICIPADA DE ASABYS, CIERRA UNA SERIES C DE $100M CON FIDELITY, EQT LIFE SCIENCES, CANAAN, KKR, ASABYS Y PFIZER Agomab Therapeutics NV(‘Agomab’) ha anunciado hoy el cierre de una ronda de financiación Serie C de 100 millones de dólares liderada por Fidelity Management & Research Company (FMR), con la participación…

Finsmes
Jul 24th, 2023
Cellcentric Receives $25M Strategic Investment From Pfizer

CellCentric, a Cambridge, UK- and and Manchester, UK-based biotechnology company, received a $25M strategic investment from Pfizer.Pfizer will support the company with its own clinical development program in multiple myeloma (MM) for 2024, alongside ongoing trials in specific haematological malignancies, through its Pfizer Ignite offering.Led by CEO Will West, CellCentric focuses on twin acetyl transferase proteins, p300 and CBP, that act as transcription co-activation factors, and that drive the expression of genes important in cancer progression. The company, which has investigated over 50 epigenetic-related targets as new ways to treat disease, and specifically cancer, was spun out from the University of Cambridge, by pioneering developmental biologist Professor Azim Surani FRS, CBE, who wanted to further explore the potential of epigenetics to deliver new treatments. In June 2023, CellCentric was granted orphan drug and fast track designation status from the FDA for inobrodib.Inobrodib works by binding to a specific part of proteins p300 and CBP (bromodomain). It is highly selective and does not impact similar pockets on other proteins. Through this action inobrodib reduces the expression of key cancer drivers: IRF4, MYC, and the androgen receptor (AR and its variants).In June 2023, CellCentric was granted orphan drug and fast track designation status from the FDA for inobrodib.As part of the collaboration, Astrid Ruefli-Brasse, Vice President, Tumour Biology, Pfizer Worldwide Research Development, will join CellCentric’s Scientific Advisory Board and Sriram Krishnaswami, Vice President and Development Head, Multiple Myeloma, Pfizer Global Product Development, will serve as an advisor to CellCentric.FinSMEs23/07/2023